Cargando…
Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure–response modelling and simulation
AIMS: We report population pharmacokinetic (popPK) and exposure–response (E–R) analyses for efficacy (induced amenorrhoea [IA]) and safety (unbound oestradiol [E2] concentrations) of the selective progesterone receptor modulator vilaprisan. Results were used to inform the dose for the Phase 3 progra...
Autores principales: | Sutter, Gabriele, Frei, Matthias, Schultze‐Mosgau, Marcus‐Hillert, Petersdorf, Kathrin, Seitz, Christian, Ploeger, Bart A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292591/ https://www.ncbi.nlm.nih.gov/pubmed/34327754 http://dx.doi.org/10.1111/bcp.15014 |
Ejemplares similares
-
Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview
por: Schultze-Mosgau, Marcus-Hillert, et al.
Publicado: (2021) -
Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020) -
Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women
por: Schultze‐Mosgau, Marcus‐Hillert, et al.
Publicado: (2020) -
Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women
por: Schütt, Barbara, et al.
Publicado: (2017) -
Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women
por: Liu, Hongzhong, et al.
Publicado: (2020)